The above list is by no means exhaustive, and other pharmacological agents that target cannabinoid 1 receptor (CB1) [128] or melanocortin 4 receptor (MC4R) [121,122], and non-steroidal anti-inflammatory drugs (NSAIDs) [129], prokinetic/gut motility enhancing agents such as metoclopramide [130], and myostatin blockers [123] are also being investigated for the treatment of cachexia. This evidence concerns the gene CNR1 and Cachexia.